KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Vincent Camus, Thierry Molina, Fabienne Desmots, Paul Blanc-Durand, Salim Kanoun, Amine Moslemi, Philippe Ruminy, Steven Le Gouill, Hervé Ghesquières, Lucie Oberic, Franck Morschhauser, Hervé Tilly, Vincent Ribrag, Roch Houot, Catherine Thieblemont, Hervé Maisonneuve, Fabien Claves, Krimo Bouabdallah, Corinne Haioun, Gandhi Laurent Damaj, Luc-Matthieu Fornecker, Robin Noel, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Wivine Bernard, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Jean-Philippe Jais, Josette Brière, Cedric Rossi, Mad-Hélénie Elsensohn, Loïc Chartier, Emmanuel Itti, Fabrice Jardin, Thierry Fest

Blood Adv 9(9) 2232-2246

PMID40030008
PMCIDPMC12088757
DOI10.1182/bloodadvances.2024015577
发表日期2025-03-03
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

The GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-day schedule) induction, followed by positron emission tomography (PET)-guided consolidation. This post hoc analysis aimed to detail the outcomes of patients with primary mediastinal B-cell lymphoma (PMBL), verified through expert pathological review and the use of gene expression profiling (GEP) and next-generation sequencing. Of 620 centrally reviewed patients, 138 (22.3%) confirmed PMBL cases were analyzed. Baseline characteristics included a median age of 33.5 years, 63.8% female, 55.1% stage III to IV, 90.6% elevated lactate dehydrogenase, 87.6% Eastern Cooperative Oncology Group performance status score of 0 to 1, 62.3% extranodal involvement, 52.6% age-adjusted International Prognostic Index (aaIPI) of 2% to 3%, and 53.6% bulk (>10 cm). Induction regimens were R/G-CHOP14 (56.9%) and R/G-ACVBP (43.1%). Postinduction treatments, based on interim PET results, included: standard consolidation chemotherapy (59.8%) if change in maximum standardized uptake value (ΔSUVmax) of >66% after cycle 2 and >70% after cycle 4 (PET2-/4-), intensive treatment and autologous transplantation (26.8%) if PET2+/4-, and salvage therapy (13.4%) if PET4+ (ΔSUVmax of ≤70%). Among patients with GEP data (n = 107), 38 (35.5%) were PDL1high/PDL2high. Key somatic mutations data (n = 87) included SOCS1 (70.1%), B2M (56.3%), STAT6 (49.4%), TNFAIP3 (47.1%), GNA13 (39.1%), CIITA (37.9%), CD58 (36.8%), and TP53 (29.9%). After a median follow-up of 39.5 months, 2-year progression-free survival (PFS) and overall survival (OS) rates were 86.2% and 93.2%, respectively. In a multivariate model including bulk, aaIPI, and ΔSUVmax PET2/PET4, only bulk and ΔSUVmax PET4 of ≤70% were associated with shorter PFS (hazard ratio, 4.39 [95% confidence interval (CI), 1.28-15.11] and 4.95 [95% CI, 1.71-14.3], respectively), whereas none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population. This trial was registered at www.ClinicalTrials.gov as #NCT01659099.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 5.

Progression-Free Survival and Overall Survival According to Interim PET2 and PET4 Response (Kaplan-Meier Analysis). (A) PFS and (B) OS according to interim PET2 and PET4 response in the PMBL set.

A

PFS

Figure 5. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:flat topline artifact曲线 3:extreme upward reversal
查看结果
B

OS

Figure 5. · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Population selection from the GAINED cohort.
非 KM Figure
Figure 2.Oncoprint showing the distribution of genomic alterations in patients with PMBL from the GAINED cohort with available targeted NGS (n = 87), clustered based on the PDL1/PDL2 gene expression status (GEP). cfDNA, baseline cfDNA level; Mut, Mutation; NA, Not available; sPDL1, baseline sPDL1 level; Synon, Synonymous mutation; Trunc, Truncating mutation.
非 KM Figure
Figure 3.Treatments received according to iPET responses. ∗One patient died before treatment start. ∗∗In patients with missing PET2 and/or PET4 data, consolidation treatments data were also missing. ∗∗∗One patient experienced treatment discontinuation after 3 cycles of R-ACVBP (toxicity). Switch for R-CHOP (n = 2 cycles) then etoposide-ifosfamide (2 cycles).
非 KM Figure
Figure 4.Progression-Free Survival and Overall Survival Curves (Kaplan-Meier Analysis). (A) PFS and (B) OS in the PMBL set.
非 KM Figure